Impact of drug discount contracts on pharmacies and on patients' drug supply

Dagmar Gröber-Grätz, Markus Gulich

► To cite this version:

Dagmar Gröber-Grätz, Markus Gulich. Impact of drug discount contracts on pharmacies and on patients' drug supply. *Journal of Public Health*, 2010, 18 (6), pp.583-589. 10.1007/s10389-010-0338-6 . hal-00542558

HAL Id: hal-00542558

<https://hal.science/hal-00542558>

Submitted on 3 Dec 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Editorial Manager(tm) for Journal of Public Health
Manuscript Draft

Manuscript Number: JOPH-D-09-00051R4

Title: Impact of drug discount contracts on pharmacies and on patients' drug supply

Article Type: Original Article

Corresponding Author: Dr. Dagmar Gröber-Grätz,

Corresponding Author's Institution: University Ulm

First Author: Dagmar Gröber-Grätz

Order of Authors: Dagmar Gröber-Grätz; Dagmar Gröber-Grätz, Dr. biol. hum. MPH; Markus Gulich, Dr. med. MSc

Abstract: Introduction: Since April 2007, health insurance funds in Germany are entitled to negotiate drug discount contracts (DDCs) with pharmaceutical manufacturers on particular drugs. DDCs commit pharmacists to dispense the drug made by this manufacturer. The aim of this study was to examine, how DDCs are implemented in pharmacies routines, and what implications DDCs have for everyday drug supply. Methods: A standardized questionnaire on DDCs and their impact on drug supply was developed according to previous literature, piloted and distributed to pharmacies in Baden-Württemberg. Results: 804 pharmacists and pharmaceutical assistants participated in the study. The implementation of DDCs implies significant extra work for pharmacists, particularly additional need for counselling and education (99.1%), additional logistical requirements and more complex data processing needs. Patients are reported to get confused (97%), angry (96.9%) about intransparent drug substitutions, medication errors occur (60.1%). Conclusion: DDCs besides implications for prescribers and patients also have substantial impact on pharmacists and pharmacies. Adverse effects on drug supply and medication safety are possible or likely.

Response to Reviewers: please find enclosed attache file "list of changes"

Impact of drug discount contracts on pharmacies and on patients' drug supply

Dr. biol. hum. Dagmar Gröber-Grätz MPH, Dr. med. Markus Gulich MSc

Department of General Practice, University of Ulm, Helmholtzstraße 20, 89069 Ulm

Dr. biol. hum. Dagmar Gröber-Grätz MPH

Department of General Practice

University of Ulm

Helmholtzstraße 20

D - 89069 Ulm

Germany

Tel.: +49 (0) 731/ 500 31105

Fax: +49 (0) 731/ 500 31109

Email: dagmar.groeber-graetz@uni-ulm.de

Impact of drug discount contracts on pharmacies and on patients’ drug supply

Introduction: Since April 2007, health insurance funds in Germany are entitled to negotiate drug discount contracts (DDCs) with pharmaceutical manufacturers on particular drugs. DDCs commit pharmacists to dispense the drug made by this manufacturer. The aim of this study was to examine, how DDCs are implemented in pharmacies routines, and what implications DDCs have for everyday drug supply. **Methods:** A standardized questionnaire on DDCs and their impact on drug supply was developed according to previous literature, piloted and distributed to pharmacies in Baden-Württemberg. **Results:** 804 pharmacists and pharmaceutical assistants participated in the study. The implementation of DDCs implies significant extra work for pharmacists, particularly additional need for counselling and education (99.1%), additional logistical requirements and more complex data processing needs. Patients are reported to get confused (97%), angry (96.9%) about intransparent drug substitutions, medication errors occur (60.1%). **Conclusion:** DDCs besides implications for prescribers and patients also have substantial impact on pharmacists and pharmacies. Adverse effects on drug supply and medication safety are possible or likely.

Keywords: drug discount contracts, pharmacists, drug switching, substitution, drug safety

List of abbreviations: DDC= drug discount contracts

Background

In Germany, a recently (April 2007) reformed federal Health Insurance Act (*Sozialgesetzbuch 5, SGB V*) entitles health insurance funds to make contracts with pharmaceutical manufacturers pertaining that members of the fund get the drug of the contract partner if prescribed an active ingredient regulated by the contract. If a patient holds a prescription of a brand name drug of a different manufacturer but the contract partner, pharmacists are liable not to hand out the prescribed but the contract-drug within certain substitution rules listed below.

Doctors may bypass the regulation for medical reasons by prescribing a brand name drug and ticking the 'aut-idem-tickbox' in the prescription form assuring that an individual patient gets hold of a particular brand name drug but discharging the Health Insurance Fund in part from their obligation to pay for the drug.

The aim of the legal regulation is to reduce expenses by cheaper drug supply.

Substitution rules include

- identical active ingredient
- identical dosage
- identical package size
- same indication

and the same or exchangeable galenics. The composition of additives (eg. alcohol, allergens, etc.) and also splitting properties of tablets to be substituted may vary (Pruszydło et al. 2008).

Despite detailed substitution rules patients have to face frequent changes in drug design and packaging.

There is evidence that substitution of drugs may result in relevant patients' confusion and medication errors (De Smet et al. 2007; Brekke et al. 2008; Sorensen et al. 2006) and that consultations with prescribing physicians are necessary (Hibbeler 2007). But it has been hardly explored what impact drug discount contracts have on the interaction of pharmacists and patients and what implication drug discount contracts have for patients' information needs.

As of August 2009, most of 186 health insurance funds and nearly 139 manufacturers participate in one or more of these discount contracts. To date, there are drug discount contracts concerning 29.206 drugs (Maag 2009) of roughly 56.660 (Pharma-Daten 2008) licensed in Germany. In 2009, the rate of rebated drugs amounts to 75% (Maag 2009). Logistics and management of substitution of such a huge amount of drugs is growing more complex and actually requires more than 18 million data sets to be controlled for in any prescription (Keller 2008). Also, logistics for procurement of drugs has become more complex and more prone to errors. In times when the first contracts started, there were often difficulties in the delivery by the pharmaceutical manufacturers. Storage capacity of pharmacies had to be extended (Hibbeler 2007).

Patients might be confused or feel frightened if they receive drugs with a modified package, similar drug names and tablets in a different shape, color or divisibility than the used one (Aronson 2004). Medication errors have been reported, the need for additional diagnostic and therapeutic procedures has been suspected and substantial individual health impact cannot be excluded. (Krämer et al. 2008, Meyer 2009, Otterbach 2008).

Additional information needs and guidance provoke increasing service times in pharmacies with impact on patient/customer satisfaction. Also pharmacies' customers get annoyed about long waiting times at the pharmacies, because the customers need additional guidance or their drug isn't available. Reliance between customer and pharmacist and drug adherence might suffer.

So far, data on the impact of drug discount contracts to pharmacists, physician and patients are sparse. The aim of this study is to investigate how DDCs are implemented and what impact they have. To have an overview over their effects, affected groups, i.e. patients, doctors and pharmacists, were interviewed by self administered questionnaire about their experience with these contracts. Results of 2 studies have been submitted for publication. Here, data about the impact of drug discount contracts on pharmacies and on patients' drug supply are reported.

Methods

For an overview of previous research on drug discount contracts a literature search in MEDLINE, EMBASE and COCHRANE was performed using keywords "drug discount contracts" or "compliance" or "tablet splitting," "drug switching" or "generic substitution" or "aut idem" or "adherence". In addition, a handsearch in german language journals such as "Zeitschrift für Allgemeinmedizin", "Deutsche Ärztezeitung" or the "Pharmazeutische Zeitung" was done.

Based on this literature review and in collaboration with pharmacists, a questionnaire for pharmacies was developed and piloted in an iterative process. The survey instrument contains sociodemographic data like age, gender, profession and years of professional practice and data about the environment of the pharmacy. Participants were asked what impact drug discount contracts have on their daily work, about their difficulties with respect to staff and storage of the additional drugs, about information need, the behaviour of the patient's

handling of the progress of substitution. Questions were answered by Likert-type answering scales ("true", "likely to be true," "tend not to be true" and "does not apply to") (Jamieson 2004).

The questionnaire was distributed as supplement in the member journal of "Landesapothekenkammer Baden-Württemberg"(Regional Chamber of Pharmacists) named "COSMAS" and was send out by the chamber to approx. 2750 pharmacies in B.-W. The questionnaire was returned anonymously to the authors.

The study was approved by the Universities internal review board (No. 190/08).

Data processing and Statistics

Data were entered in a SAS database randomly controlled for correct input and evaluated by means of descriptive statistics. All variables were initially evaluated descriptively, analytical statistics was performed if applicable.

Results

The survey was conducted between September – December 2008. 804 questionnaires were returned from pharmacists (82.3%), PTA (pharmacist`s assistant) (13.7%) and PKA (pharmaceutical sales assistant) or other professions (4%) (PKA/other). 38% of respondents are male.

In table 1 basic characteristics of the sample are presented.

Furtheron, responses are reported without reference to professional level, unless otherwise noted.

Table 1**Presentation of individual items**

A substantial majority of respondents (69%) report that they rarely get prescriptions that exclude substitution (“aut-idem-tickbox” ticked), and 30.9% report they get some such prescriptions.

According to pharmacists`questionnaire, they usually (82.5% on a Likert scale) receive prescriptions with the drug`s brand name on it. In contrast to other European countries, German pharmacists seldom receive prescriptions with the drug`s active ingredient noted (79.8% rejection on a Likert scale) (Figure 1).

Figure 1

A vast majority of respondents (98.3%) often have to switch drugs due to DDCs, and almost half of them (45.3%) admit that they occasionally do not have appropriate drugs for substitution in stock. 45.1 % report shortages of supply of appropriate drugs, and some 31% have encountered delivery problems of these drugs. Less than one fourth did not have substantial (21.6%) or did not have any (1.9%) supply problems with discount-drugs.

One of the critiques against drug substitution is that splitting properties of tablets might differ substantially. 65.7 % (48.4 + 17.3) of pharmacists or their employees don`t know exactly about the splitting properties of individual drugs handed over to patients (Figure 2).

Figure 2

Almost all respondents (96.9%) report that customers react angry about getting an unknown drug. 97% of interviewees note that in their opinion the patients feel confused about handling of their drugs resulting from DDCs. Furthermore, 60.1% respondents specify that they know about medications errors of patients due to DDCs (Figure 3).

Figure 3

A vast majority (99.1%) report increased need for patients` counselling. 99.3% stated that the discount contracts have an important impact on the daily business. 93.8% indicate additional personnel expenses with respect to additional delivering services of drugs to the patients. In

Germany if a specific drug is not on stock in the pharmacy they order it and will deliver the medication to patient's home, usually on the same day (Figure 4).

Figure 4

In table 2, we present the results concerning extra payments, customers behaviour with respect to swapping drugs and additional patients' waiting time due to DDC.

About 85% (24.5% and 59.9 % respectively) of respondents note that it happens more than 5 times a week, that patients ask for not substituting their previously known drug, and 70 % (27.9 % and 42.2 % respectively) say that at least 5 times a week customers not only ask for, but insist on receiving their known drug. Likewise customers have to accept additional waiting time due to increased counselling and occasionally even higher surcharges. Furthermore over 70% report that they got threats of repayments ("Retaxierung") by the health insurances up to 10 times per month (Table 2).

Table 2

Discussion

By reforming the Health Insurance Act in 2007 and implementing drug discount contracts, new instruments have been effective in the regulation of drug supply installed with the aim to reduce cost for the Health Insurance Funds.

Pharmacists now are overwhelmed by the sheer amount of 28.000 DCCs they have to control for each individual patient's medication.

The administration of drug discount contracts denotes a significant additional burden for pharmacies. This arises primarily due to the significant demand for explanation by the patient, manpower requirements, the challenging logistics and the technical processing of data. Additional personnel expenses by an additional service (delivery service) and a high increase of advice required by the customers have an important influence on the daily business. Also, half of the pharmacists do not know exactly if the substitution tablet is as well and exact divisible as the substituted one was. They must additionally look up in the Formulary. Pharmacists do have an increased need for patient-information and consultation due to the discount contracts.

But not only pharmacists bear an additional burden by the DDCs. Patients showed the same inconvenience. Medication errors do occur (Rücker et al.; Mahler et al). It is evident that patients feel confused and angry because of the substitution (Rücker 2007; Wahl 2008). This also reflects in patients' behavior towards pharmacists, because patients very often insist on or ask for their well-known medicine. Patients have more waiting time because of more additional advice or by delivery problems of the pharmaceutical companies (Haffke 2008).

Physicians might specify not to change the prescribed drug on the prescription form to make sure that the patient continues to receive his usual medication. According to surveys by the „Kassenärztlichen Vereinigung Nordrhein“ (Association of Statutory Health Insurance Physicians, Northrhine) majority of physicians never or only in individual cases are ticking the box “aut idem” (Neye 2008). This may be, because physicians are held liable for uneconomic prescription, on the part of the health insurance companies (Manthey 2008). Same applies for pharmacists. If they do not deliver the particular rebate drugs of the health insurance companies' contractors, they might be held liable in a procedure called “Retaxierung” for additional costs of non-contractors' drugs by the health insurance funds (Ehlers et al. 2001).

Now, with DCCs in effect, health insurance funds directly interfere with historically evolved structures in the health care system. DCCs impose a fundamental reorganization of Germany's drug supply by administrative means. Pharmacies' and pharmacists' self-concept and relationship to customers changes fundamentally.

In the long run, pharmacies in Germany might have to give up their traditional role as an independent player and stakeholder in the health care system and turn more into a “dispensary-style” pharmacy to hand out a drug previously negotiated between health care funds and drug manufacturers.

Limitations of the study

Fundamental limitation of this study is the restriction to self reported appreciation of the impact of DDCs of pharmacists' poise/attitude to medication supply and to self reported behaviour. No direct observations of pharmacists' were made, reliability of pharmacists' statements remains unknown. In this study, patients' attitudes have only been reported by best

guess of pharmacists, no direct patient-generated data was part of this manuscript. Data of physicians' and patients' self reported attitudes are reported elsewhere.

Due to a lack of basic data, this study could not be designed to evaluate effect size of DDCs' impact on patients' drug supply, medication adherence, potential adverse events and patients' well being.

Conclusion

The DDCs denote a significant intervention in drug therapy. Pharmacists report on medication errors on the part of patients because of the discount contracts. Medication safety seems to be at risk. Further studies e.g. analysis of secondary data and for direct observations are necessary to evaluate the effect of these contracts agreements. The aim of the discount contracts should not focus on monetary aspects alone. One of the major ethical aims of modern medicine is respect for patients' autonomy and it might be affected by DDCs.

Acknowledgment

We would like to thank the "Landesapothekenkammer Baden-Württemberg" specially Mr. Karsten Wurzer. Without their help this investigation would not be possible. We also thank all participants of all professions in the pharmacies for contribution.

Conflict of interest

The authors declare that they have no conflict of interest.

Literatur

- Aronson JK (2004) Medication errors resulting from the confusion of drug names. *Expert Opin Drug Saf* 3:167-72
- Brekke M, Rognstad S, Straand J, et al (2008) Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study. *Scand J Prim Health Care* 26:80-5
- De Smet PA, Denneboom W, Kramers C, Grol R (2007) A composite screening tool for medication reviews of outpatients: general issues with specific examples. *Drugs Aging* 24:733-60
- Ehlers PE, Weizel I (2001) Die geplante aut-idem Regelung - organisierte Verantwortungslosigkeit oder cleveres Sparmanagement? *Pharm Ind* 63:1156-1158
- Haffke D (2008) Rot statt Grün - Hoffnung auf Einsparungen für die einen, Gefahr für die Patientenversorgung für die anderen. Rabattverträge standen im Mittelpunkt des 4.

- Zwischenahner Dialogs. Niedersächsisches Ärzteblatt 05
http://www.haeverlag.de/nae/n_beitrag.php?id=2152
- Hibbeler B (2007) Deutscher Apothekertag: Rotes A gegen grünes Kreuz. Dtsch Ärztebl 104:A-2691 / B-2381 / C-2309
- Jamieson S (2004) Likert scales: how to (ab)use them. Med Educ 38:1217-8
- Keller (2008) Zahl der Rabatt-Arzneimittel steigt auf knapp 25.000. Deutsches Ärzteblatt
<http://www.aerzteblatt.de/v4/news/news.asp?id=34100>
- Krämer G, Elger C, Denning D, Neubauer BA und Ad hoc-Kommission der Deutschen Gesellschaft für Epileptologie (2008) Aut-idem-Ankreuzen: bei Antiepileptika wichtiger denn je! Z Epileptol 2:79-81
- Leutgeb R, Mahler C, Laux G, Weschnetz A, Szecsenyi J (2009) Health insurance discount contracts: problems and risks for the general practitioner in the medical care of patients with chronic illness. Dtsch Med Wochenschr 134:181-6
- Maag S (2009) IMS Health .Der Arzneimittelmarkt der Gesetzlichen Krankenversicherung im August 2009.
http://www.imshealth.de/sixcms/media.php/16/Kommentierte%20Grafiken%20IMS%20Marktbericht%202008_2009.pdf
- Mahler C, Jank S, Hermann K, Haefeli WE, Szecsenyi J (2009) Information on medications - How do chronically ill patients assess counselling on drugs in general practice? Dtsch Med Wochenschr 134:1620-4
- Manthey A (2008) Rabattmedikamente: Krankenkasse droht Ärzten mit Wirtschaftlichkeitsprüfungen. <http://www.aerzteblatt.de/v4/news/news.asp?id=34777>
- Meyer F (2009) Das Kreuz mit dem Kreuzchen - Riskante "aut-idem"-Substitution. Der Allgemeinarzt 5:20-21
- Nye H (2008) Rabatt-und Risk-Share-Verträge in der Auswirkung auf das Verordnungsverhalten der Ärzte.
http://www.kvno.de/importiert/focus/neye_20080528_focus.pdf
- Otterbach I (2008) Medikamente in doppelter Dosis. Ärztemagazin 25:20-21
- Pharma-Daten 2008 (2008) Bundesverband der Pharmazeutischen Industrie e.V. (BPI)
- Pruszydlo MG, Quinzler R, Kaltschmidt J, Haefeli WE (2008) Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany. Dtsch Med Wochenschr 133:1423-8
- Rücker D (2007) Patienten fühlen sich schlecht versorgt. Pharmazeutische Zeitung online
<http://www.pharmazeutische-zeitung.de/index.php?id=3093>
- Sorensen L, Stokes JA, Purdie DM, Woodward M, Roberts MS (2006) Medication management at home: medication risk factor prevalence and inter-relationships. J Clin Pharm Ther 31:485-91
- Sozialgesetzbuch (SGB) Fünftes Buch (V) - Gesetzliche Krankenversicherung - (SGB V).
www.buzer.de/gesetz/2497/index.htm.
- Wahl H (2008) Rabattverträge: Sinn und Vorgaben gesetzlicher Vorgaben. Der Diabetologe 4:64-67

Figure 1: Evaluation of the prescriptions. (Results of a four step Likert scale)

Figure 2 : Evaluation of the discount agreements with respect to storage, shortages of supply, the frequency of switching drugs and the knowledge of splitting of the tablets. (Results of a four step Likert scale – DDC= drug discount contracts)

Figure 3: Evaluation of the drug discount contracts with respect to customers behaviour, medications intake and medications errors. . (Results of a four step Likert scale - DDC= drug discount contracts)

Figure 4: Evaluation of the discount agreements with respect to advice, additional personnel and the influence on the day-to-day business. (Results of a four step Likert scale - DDC= drug discount contracts)

Table 1: Age, years of profession by pharmacists, PTA, PKA/ other professions and pharmacy environment

			n	minimum	median	maximum	mean	SD
Age (years)	Pharmacists	male	289	26	53	86	51.9	10.4
	Pharmacists	female	337	25	47	83	47	10.5
	PTA	male	-	-	-	-	-	-
	PTA	female	105	17	37	60	36.8	11.1
	PKA/other	male	-	-	-	-	-	-
	PKA/other	female	31	19	45	64	43.5	12.8
years of profession			< 2 years		2-5 years	5-20 years	> 20 years	
			Pharmacists		1.1%	5.7%	34.9%	58.3%
			PTA		9.4%	12.2%	45.8%	32.7%
			PKA/other female		6.5%	6.5%	32.3%	54.8%
Pharmacy environment			rural		suburb/provincial		rather metropolitan	
			36.8%		48.9%		14.4%	

Table 2: Additional communication between pharmacies and customers. Financial performance and additional waiting time for customers to switch medications based on the drug discount contracts

	never	quite rare	often
Does it happens that customers have to pay more extra payment than before implementation of DDCs?	10.4%	80%	9.6%

	never	<5 times	5-10 times	> 10 times
During the last week, how often have customers asked for their well-known drug?	0.5%	15.1%	24.5%	59.9%
During the last week, how often did customers insist on their well-known drug?	0.4%	29.6%	27.9%	42.2%
During the last week, how often did customers suffer delay of delivery, because the discounted drug was out of stock?	0.6%	16.4%	23.9%	59.1%

	yes	no
Did your pharmacy get a threat of “Retaxierung”, which means financial loss by health insurance companys	70.1%	29.9%

	<5 times	5-10times	> 10 times
If yes. how many on average per month?	10.4%	80%	9.6%

List of changes

1. If a patient holds a prescription of a brand name drug of a different manufacturer but the contract partner, **pharmacists....**
2. Based on this literature review and in collaboration with pharmacists, a questionnaire for pharmacies was developed and piloted in **an** iterative process.
3. 93.8% indicate additional personnel expenses with respect to additional delivering services of **drugs** to the patients.
4. In Germany if a specific drug is not on stock in the pharmacy they order it and will deliver the medication to patient's home, usually on the same day (Figure 4).
~~Germany, traditionally, there is a service of lots of pharmacies. If a specific drug is not available, an employee will deliver medication to the patient's home, usually on the same day (Figure 4).~~
5. Additional personnel expenses by an additional service (delivery service) and a high **increase of advice required by the customers** have an important influence on the daily business.
6. This also reflects in patients' behavior towards pharmacists, because patients very often insist on or ask for their well-known medicine.
~~This also reflects patient in behavior towards pharmacists, because patients very often insist or ask for their well-known medicine".~~
7. Patients ~~(do)~~ have more waiting time because of more additional advice or by delivery problems of the pharmaceutical companies (Haffke 2008).
8. In the long run, pharmacies in Germany might have to give up their traditional role as an independent players **s** and stakeholders **s** in the health care system